Table 3.
KRAS mutation status of the primary tumor and the CTC DNA in 58 patients; in 20 cases no primary tissue was available.
| KRAS mutation status | CTC DNA Sample (n = 58) | Primary Tumor Sample (n = 38) |
|---|---|---|
| Wild type (GGTGGC) (CTC cyto positive) | 11 | 1 |
| All KRAS mutations* | 57 | 44 |
| KRAS G12V (GTT)* | 14 | 16 |
| KRAS G12D (GAT)* | 21 | 22 |
| KRAS G13S (AGC)* | 5 | 2 |
| KRAS G13D (GAC)* | 8 | 4 |
| KRAS G12C (TGT)* | 2 | — |
| KRAS G12S (AGT)* | 6 | — |
| KRAS G12A (GCT)* | 1 | — |
| multiple KRAS mutations | 11 | 7 |
*Eleven patients had multiple mutations – all mutations are shown here; 6 patients with a KRAS G12D mutation had one additional mutation, and 3 patients with a KRAS G12V mutation had one additional mutation in their CTC. 4 patients had a combination of a KRAS G12V and a KRAS G12D mutation in the primary tumor.